Natural history of thromboembolism in AL amyloidosis

To determine the natural history of thromboembolism in patients with biopsy-proven AL amyloidosis, medical records of 2,132 patients evaluated at Mayo Clinic between 1975 and 2000 were reviewed. Forty patients (21 male) were found to have objectively documented thromboembolism. The median age was 65 years. Four patients had a monoclonal gammopathy of undetermined significance, 20 had an unspecified plasma cell proliferative disorder, 11 had multiple myeloma, and 1 had Waldenström macroglobulinemia. Twelve patients had cardiac amyloid, and 20 had renal amyloid. Neither the extent of the amyloid nor the type of monoclonal protein was predictive of the development of thromboembolic events. Thromboembolism preceded the diagnosis of AL amyloidosis in 11 patients, occurred at the time of diagnosis or within 1 month after diagnosis in 11 patients, and occurred 1 month or more after diagnosis in 18 patients. Twenty-nine patients (73%) had venous thrombosis and 11 (28%) had arterial thrombosis. Eight patients (20%) died within 1 month after the thrombotic event, and 18 (45%) died within 1 year. The development of thrombosis in patients with AL amyloidosis appears to predict significant mortality within the first month and year after the event.

[1]  T. Nickolas,et al.  Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. , 2003, Seminars in nephrology.

[2]  P. Thodiyil,et al.  Variation in Relative Risk of Venous Thromboembolism in Different Cancers , 2002, Thrombosis and Haemostasis.

[3]  S. Rajkumar,et al.  Deep venous thrombosis and thalidomide therapy for multiple myeloma. , 2001, The New England journal of medicine.

[4]  G. Palladini,et al.  Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. , 1999, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[5]  M. Pepys,et al.  AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS , 1997, British journal of haematology.

[6]  F. Cools,et al.  Primary systemic amyloidosis complicated by massive thrombosis. , 1996, Chest.

[7]  J. V. Sørensen,et al.  Venous thromboembolism and cancer. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[8]  W. Hager,et al.  Amyloid heart disease manifested by systemic arterial thromboemboli. , 1992, Chest.

[9]  M. Skinner,et al.  Bleeding manifestations in 100 patients with amyloidosis. , 1983, JAMA.

[10]  H. Lackner Hemostatic abnormalities associated with dysproteinemias. , 1973, Seminars in hematology.

[11]  D. Catovsky,et al.  Thromboembolic Complications in Myelomatosis , 1970, British medical journal.

[12]  B. Barlogie,et al.  Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.

[13]  J. Buxbaum,et al.  The systemic amyloidoses. , 1998, The New England journal of medicine.

[14]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.

[15]  C. Hollak,et al.  Management of Gaucher disease. Current status and future directions: A roundtable discussion. , 1995 .

[16]  R. Kyle,et al.  Amyloidosis (AL). Clinical and laboratory features in 229 cases. , 1983, Mayo Clinic proceedings.